{"id":13204,"date":"2020-11-03T12:33:05","date_gmt":"2020-11-03T20:33:05","guid":{"rendered":"https://www.realself.com\/news\/?p=13204"},"modified":"2024-04-09T07:22:51","modified_gmt":"2024-04-09T14:22:51","slug":"new-fillers-neurotoxins","status":"publish","type":"post","link":"https://www.realself.com\/news\/new-fillers-neurotoxins","title":{"rendered":"5 New Fillers and Neurotoxins You Can Expect Soon\u2014and 2 That Just Launched"},"content":{"rendered":"

According to a report<\/a> published by the American Society of Plastic Surgeons<\/em>, there were more than 7.4 million botulinum toxin type A injections and 2.6 million soft-tissue filler injections performed in 2018—and those numbers are only expected to have risen since. Not only does the demand for injectables continue to grow, but the expansion of new formulas is evolving too. From toxins that last impressively long to fillers made for sensitive skin, these next few years are expected to be exciting for cutting-edge noninvasives. We spoke to the experts about what makes these products different from the others and why we should be excited about them. <\/p>

New Neurotoxins Expected in the Next Few Years<\/h2>

Daxibotulinum toxin (or DAXI) by Revance<\/strong><\/h3>

DAXI, a new botulinum A toxin for glabellar wrinkles<\/a>, is developed by Revance and is not yet approved in the U.S. or any other country. “What sets this toxin apart from the rest is that studies<\/a> have indicated that at the injected dose, the duration is longer than [that of] the current market botulinum toxin dosings,” says Dr. Joely Kaufman<\/a>, a board-certified dermatologist in Coral Gables, Florida. “DAXI has a proprietary peptide [that] differs from our currently available botulinum type A toxins.”<\/p>

According to Dustin Sjuts, chief commercial officer at Revance, DAXI is a next-generation neuromodulator product that’s anticipated to launch following a U.S. Food and Drug Administration (FDA) approval, expected to happen in the latter part of this year. “DAXI is the first and only neuromodulator product [that] combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components,” says Sjuts. Dr. Sapna Palep<\/a>,  a board-certified dermatologist in New York City, is also excited about the release of DAXI, for multiple reasons. “It’s taking the longevity of neuromodulators from 12–16 weeks to an average of 24 weeks<\/a>,” says Dr. Palep. “[The claim is] a response rate of 95%, which is impressive.<\/a>” <\/p>

Find Doctors Near You<\/a><\/div>

Bonti botulinum toxin by Allergan<\/strong><\/h3>

Bonti is the new toxin being developed by Allergan. “This product should have an extremely quick onset of action [within 24 hours] but have a short effect, lasting two to four weeks” says Dr. Joshua Zeichner<\/a>, a board-certified dermatologist in New York City. “It will be a great option for first-timers wanting to try out a treatment and can also help people who need a last-minute touch-up before a big event.”<\/p>

Related: Injectable Bruises? Been There. Here’s How to Handle Them Without Hiding Out.<\/a><\/em><\/p>

New Dermal Fillers Expected in the Next Few Years<\/h2>

Juvéderm<\/strong> Volite <\/strong><\/h3>

Available only in Europe and Canada, Juvéderm Volite is not a dermal filler but rather an injectable treatment intended to improve skin quality for up to nine months. Volite contains skin-conditioning hyaluronic acid (HA) gel, to help reduce the appearance of fine lines while also helping the overall tone and texture of the skin itself. The main goal for this treatment is to help make the face look more hydrated rather than diminish the appearance of wrinkles or add volume to the face. Not only is Volite used to hydrate the skin thanks to HA’s high water-binding capacity, but it also helps increase overall elasticity too. Word from Allergan is that we’ll have to wait until 2021 for this product to hit the U.S. market.  <\/p>

Juvéderm<\/strong> Volux<\/strong><\/h3>

Juvéderm Volux is another hyaluronic acid (HA)-based dermal filler designed to replace lost facial volume. Volux is denser than many fillers on the market—it’s made to mimic bone—and creates a more lifted look. Because the consistency of the product is so dense, it’s often used in the jawline and chin area, to sculpt the area.Volux isn’t available in the U.S. just yet, and like Juvéderm Volite, most likely won’t be available until 2021. <\/p>

ProfHilo<\/strong><\/h3>

ProfHilo<\/a> is a hyaluronic acid (HA) treatment that helps with skin laxity, and it’s  free of 1,4-butanediol diglycidyl ether (BDDE). BDDE is a liquid, hygroscopic in nature, that links the HA chains to prevent them from being broken down by the body. ProfHilo is unique because it’s able to remain stable and effective without<\/em> BDDE. And while BDDE is safe in small doses in dermal filler, the fact that ProfHilo is BDDE-free really appeals to those consumers who are cautious of having synthetic chemicals used in their dermal fillers. It also hydrates and can improve elasticity in the skin, leading to a firmer, more youthful appearance. The injectable is currently available only in Europe and isn’t expected to launch in the United States until next year. <\/p>

Find Doctors Near You<\/a><\/div>
\n